Emergingdx Inc.

Emergingdx Inc. is a for-profit subchapter S corporation headquartered in Lowell, Massachusetts, specializing in advanced diagnostic and biosensor technologies for medical research and precision medicine applications. The company has established itself as a small business innovator focused on developing sophisticated diagnostic platforms for both military and civilian healthcare sectors, leveraging expertise in multiplexed omics, microRNA detection, and pathogen identification. Through its federal contract and grant portfolio, Emergingdx has demonstrated significant capability in translating cutting-edge diagnostic innovations into operationally relevant solutions for defense health and research institutions.

Emergingdx Inc. has secured an extensive portfolio of federal contracts totaling approximately $7.6 million across multiple research and development initiatives, all designated as total small business set-asides. The company's contract work has been primarily supported by two defense agencies: the Defense Health Agency (DHA) and the Office of Naval Research (ONR). Key contract deliverables include the development of multiplexed diagnostic platforms for invasive fungal infections, rapid automated multiplexed omics platforms, automated detection platforms for circulating and exosomal microRNAs, integrated multiplexed low-cost diagnostic platforms for rapid microbial identification, and multiplexed biosensors for rapid detection of multi-omics biomarker panels. Emergingdx's contract awards span multiple research phases, including ten SBIR Phase I awards, two SBIR Phase II awards, three STTR Phase I awards, and two STTR Phase II awards. The company has not utilized major subcontractors on these awards, performing the research and development work primarily at its Lowell or Mansfield, Massachusetts facilities. Most recently, the company secured a $2.0 million STTR Phase II contract from ONR (awarded September 30, 2025, completing October 1, 2029) and a $1.3 million SBIR Phase II contract from DHA (awarded September 26, 2025, completing January 25, 2028), both representing advancement in diagnostic platform development and reflecting continued confidence in the company's innovation capabilities.

Emergingdx Inc. has received one prime federal grant award through the Institute of Food Production and Sustainability, a $249,837 project grant awarded on July 1, 2023, with completion scheduled for February 28, 2025. This grant focused on addressing a significant disease limiting U.S. aquaculture production, specifically the development of simple yet sensitive on-site diagnostics for monitoring Flavobacterium psychrophilum (FP), a major pathogen impacting salmonid aquaculture production. The grant program emphasized breaking vertical transmission of FP through infected gametes, an identified major vehicle of pathogen spread in aquaculture commerce. The grant represents Emergingdx's diversification beyond defense-focused healthcare diagnostics into agricultural production support, demonstrating the transferability of the company's multiplexed diagnostic platform technology to improve agricultural productivity and farm-based pathogen monitoring.

Research and Development, Product and Technology Development, Commercialization, Venturing